The Russian president thought he could outlast the opprobrium of the easily distracted West. It's a gamble he's lost
With few new buyers, the superjumbo's fate is up in the air
Instead of fighting for more regulations, they're pushing for market-based solutions
Vessel wants YouTube stars to focus on another platform
JPMorgan's chief helps kill a Dodd-Frank rule and does the heavy lifting for Wall Street
MetaMind customizes its deep-learning software for businesses that want to learn faster
The final installment of "Serial," a cult-favorite podcast about a murder, will begin just like every other episode—with the name of a prison telecom provider
"These colleges are ranked the top in the country, and it's surprising to me that they can't send out a simple email."
Customer service is one area where small businesses can beat big-box competitors
Founders: Jeff Stein, John Finn, and John Schmid
VC Investment over the last four quarters: $35.16 million
Founded in 2004, the 35-employee biopharmaceutical company is working to develop antibacterial drugs to treat infections caused by resistant bacteria. Besides the VC investment, Stein says Trius has raised $32 million in government grants and contracts. As far as his perspective on the impact of the recession on his company, which expects less than $1 million in revenues in 2008, Stein says it will make the fundraising environment more challenging and may impact the partner environment as well.
Key to startup success: "Recruit top-tier executives. Focus on advancing your most valuable asset and seek alternative financing for earlier-stage programs."